Skip to content

The latest company news, press releases, and resources about Servier and everything our company has to offer.

Advanced Search
  • servier logo
     
    12.21.2020
    Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
  • servier logo
     
    12.21.2020
    Servier to Acquire Agios Pharmaceuticals' Oncology Business
  • servier logo
     
    12.04.2020
    Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
  • servier logo
     
    11.04.2020
    Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
  • servier logo
     
    10.16.2020
    Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
Show 5102550100 per page
Media Contacts

Servier Media Relations
us2mediarelations@servier.com

Subscribe